FDA Approves Carfilzomib Label Update in Myeloma

January 17, 2018 – The FDA has approved a supplemental new drug application that adds overall survival (OS) data from the phase III ENDEAVOR trial to the label for carfilzomib for use in patients with relapsed or refractory multiple myeloma. Results from the primary ENDEAVOR OS analysis published in the Lancet Oncology showed that carfilzomib reduced the risk of death by 21% compared with bortezomib in patients with relapsed/refractory multiple myeloma. Carfilzomib … (leggi tutto)